This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.
Aged 4 to 80 years
Evidence of high-risk hematopoietic malignancy with relapsed/refractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma
Karnofsky/Lansky score of ≥ 50
Agree to use contraceptive measures during study protocol participation (when age appropriate)
Patients with uncontrolled infections
Pregnancy or lactating
History of prior fluorothymidine allergy or intolerance.
University of Oklahoma
Lead sponsor
Emory University
Collaborator